Balancing the Burden of Treatment for nAMD and DME Through Innovative Therapeutics and Surgical Delivery Systems: Are We Losing Sight of Emerging Options?

Author(s)/Faculty: Arshad M. Khanani, MD, MA; Caroline Baumal, MD; Carl D. Regillo, MD, FACS
Release Date: 1/7/2022Expiration Date: 1/6/2023
Credit Type: CME / CME with ABO Continuing Certification Number of Credits: 1.25
Content Type: LectureProvider:
Novel delivery systems, gene therapy, as well as agents with unique mechanisms of action that extend dosing frequency, are being assessed in clinical studies for the management of neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME). These innovative approaches aim to address the unmet needs of treatment burden and suboptimal treatment responses often seen in patients with retinal diseases. Unlike intravitreal injections, several of these new therapeutic modalities require specific surgical approaches that must be utilized to provide optimal outcomes and safety. In this CME activity, experts in the field will evaluate the latest efficacy and safety data for novel delivery systems and therapies with unique mechanisms of action that have the potential to lengthen the interval between treatments for nAMD and DME, as well as discuss best practices and procedures that can reduce complications with new therapeutic modalities that require unique surgical approaches.